Authors
Robert BM Landewé, Féline PB Kroon, Alessia Alunno, Aurélie Najm, Johannes WJ Bijlsma, Gerd-Rüdiger R Burmester, Roberto Caporali, Bernard Combe, Richard Conway, Jeffrey R Curtis, Ori Elkayam, Laure Gossec, Marloes W Heijstek, Lukas Haupt, Annamaria Iagnocco, John D Isaacs, István Ábel Juhász, Suzi Makri, Xavier Mariette, Iain B McInnes, Puja Mehta, Ulf Mueller-Ladner, Hendrik Schulze-Koops, Josef S Smolen, Dieter Wiek, Kevin L Winthrop, Victoria Navarro-Compán, Pedro M Machado
Publication date
2022/12/1
Journal
Annals of the rheumatic diseases
Volume
81
Issue
12
Pages
1628-1639
Publisher
BMJ Publishing Group Ltd
Description
The first EULAR provisional recommendations on the management of rheumatic and musculoskeletal diseases (RMDs) in the context of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), largely based on expert opinion, were published in June 2020. Since then, an unprecedented number of clinical studies have accrued in the literature. Several SARS-CoV-2 vaccines have been approved for population-wide vaccination programmes in EULAR-affiliated countries. Studies regarding vaccination of patients with (inflammatory) RMDs have released their first results or are underway.
EULAR found it opportune to carefully review to what extent the initially consensus expert recommendations stood the test of time, by challenging them with the recently accumulated body of scientific evidence, and by incorporating evidence-based advice on SARS-CoV-2 vaccination. EULAR started a formal (first) update in …
Total citations
Scholar articles
RBM Landewé, FPB Kroon, A Alunno, A Najm… - Annals of the rheumatic diseases, 2022